Reflections on World Thrombosis Day 2024

On the occasion of World Thrombosis Day, our four journals: Thrombosis and Haemostasis, TH Open, Seminars in Thrombosis and Hemostasis as well as Hämostaseologie—Progress in Haemostasis join forces in a collaborative editorial to share and emphasize our commitment to advancing research, education, and clinical practice, and reducing the impact of thrombosis worldwide, as an entity that gives rise and contributes to a major part of the morbidity and mortality from cardiovascular diseases and beyond.

We highlight here recent publications from our journals, which we hope will have an impact on understanding and management of thrombosis.

^* These authors serve as co-corresponding authors.

Publication History

Article published online:
13 October 2024

• References

• 1 Sachetto ATA, Mackman N. Monocyte tissue factor expression: lipopolysaccharide induction and roles in pathological activation of coagulation. Thromb Haemost 2023; 123 (11) 1017-1033
• 2 Rolling CC, Sowa MA, Wang TT. et al. P2Y12 inhibition suppresses proinflammatory platelet-monocyte interactions. Thromb Haemost 2023; 123 (02) 231-244
• 3 Zou J, Sun S, De Simone I. et al. Platelet activation pathways controlling reversible integrin αIIbβ3 activation. TH Open 2024; 8 (02) e232-e242
• 4 Bourne JH, Smith CW, Jooss NJ. et al. CLEC-2 supports platelet aggregation in mouse but not human blood at arterial shear. Thromb Haemost 2022; 122 (12) 1988-2000
• 5 Boccatonda A, Balletta M, Vicari S, Hoxha A, Simioni P, Campello E. The journey through the pathogenesis and treatment of venous thromboembolism in inflammatory bowel diseases: a narrative review. Semin Thromb Hemost 2023; 49 (07) 744-755
• 6 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
• 7 Chao TF, Chan YH, Chiang CE. et al. Early rhythm control and the risks of ischemic stroke, heart failure, mortality, and adverse events when performed early (<3 months): a nationwide cohort study of newly diagnosed patients with atrial fibrillation. Thromb Haemost 2022; 122 (11) 1899-1910
• 8 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2024; 124 (02) 135-148
• 9 Tafur AJ, Barnes GD, Bhagirath VC, Douketis J. Anticoagulation stewardship to bridge the implementation gap in perioperative anticoagulation management. TH Open 2024; 8 (01) e114-e120
• 10 Spiezia L, Campello E, Tormene D, Simioni P. Venous thromboembolism in children: the rivaroxaban experience. Semin Thromb Hemost 2024; 50 (06) 866-872
• 11 Glonnegger H, Glatthaar N, Eckenweiler M. et al. Laboratory findings, medical imaging, and clinical outcome in children with cerebral sinus venous thrombosis. Hamostaseologie 2023; 43 (03) 188-195
• 12 Pleming W, Barco S, Voci D. et al. Cardiac and cerebral arterial complications of Lemierre syndrome: results from a systematic review and individual patient data meta-analysis. Hamostaseologie 2022; 42 (04) 261-267
• 13 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
• 14 Campello E, Bucciarelli P, Catalani F, Erba N, Squizzato A, Poli D. Scientific Reviewer Committee. Anticoagulant therapy in pregnant women with mechanical heart valves: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) position paper. Thromb Haemost 2024; 124 (08) 695-708
• 15 Aguirre Del-Pino R, Monahan RC, Huizinga TWJ, Eikenboom J, Steup-Beekman GM. Risk factors for antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2024; 50 (06) 817-828
• 16 Benz AP, Xu L, Eikelboom JW. et al; ANNEXA-4 Investigators. Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban. Thromb Haemost 2022; 122 (06) 998-1005
• 17 Goldin M, Smith K, Koulas I. et al. Clinical pathways and outcomes of andexanet alfa administration for the reversal of critical bleeding in patients on oral direct factor Xa inhibitors. TH Open 2024; 8 (02) e209-e215
• 18 Leebeek FWG, Castaman G, Marier JF. et al. Exposure-response relationship between VWF/FVIII activity and spontaneous bleeding events following recombinant VWF prophylaxis in severe VWD. TH Open 2024; 8 (02) e243-e251
• 19 Khaddam D, McRae HL, Schwarz N. et al. High prevalence of F2 20210G > A in splanchnic vein thrombosis and cerebral venous sinus thrombosis: a retrospective cohort study of patients with thrombosis in atypical sites. Hamostaseologie 2024; (e-pub ahead of print)
• 20 Verstraete A, Freson K, Verhamme P, Vanassche T. Thrombophilia testing: from genetic predisposition to discrimination. TH Open 2024; 8 (02) e177-e180
• 21 Uzun G, Althaus K, Hammer S. et al. Diagnostic performance of a particle gel immunoassay in vaccine-induced immune thrombotic thrombocytopenia. Hamostaseologie 2023; 43 (01) 22-27
• 22 Rolling CC, Mohme M, Bokemeyer C. et al. Circulating tumor cells and thromboembolic events in patients with glioblastoma. Hamostaseologie 2024; (e-pub ahead of print)
• 23 Romiti GF, Guo Y, Corica B, Proietti M, Zhang H, Lip GYH. mAF-App II trial investigators. Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mAFA-II randomized clinical trial. Thromb Haemost 2023; 123 (11) 1042-1048
• 24 El-Sherbini AH, Coroneos S, Zidan A, Othman M. Machine learning as a diagnostic and prognostic tool for predicting thrombosis in cancer patients: a systematic review. Semin Thromb Hemost 2024; 50 (06) 809-816
• 25 Franchini M, Focosi D, Pezzo MP, Mannucci PM. Catastrophic thrombosis: a narrative review. Semin Thromb Hemost 2024; (e-pub ahead of print)